Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

QLGN

Qualigen Therapeutics Inc

Jun 18 • 04:00PM ET

0.1870

Dollar change +0.0122
Percentage change 6.98	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.53	Insider Own	10.70%	Shs Outstand	6.79M	Perf Week	-7.59%
Market Cap	1.27M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	6.06M	Perf Month	-36.18%
Income	-12.81M	PEG	-	EPS next Q	-	Inst Own	4.13%	Short Float	1.32%	Perf Quarter	-47.13%
Sales	3.23M	P/S	0.39	EPS this Y	-	Inst Trans	1.38%	Short Ratio	0.49	Perf Half Y	-67.65%
Book/sh	-0.39	P/B	-	EPS next Y	-	ROA	-122.88%	Short Interest	0.08M	Perf Year	-80.32%
Cash/sh	0.06	P/C	3.17	EPS next 5Y	-	ROE	-505.62%	52W Range	0.14 - 1.26	Perf YTD	-66.00%
Dividend Est.	-	P/FCF	-	EPS past 5Y	71.09%	ROI	-	52W High	-85.16%	Beta	-0.82
Dividend TTM	-	Quick Ratio	0.28	Sales past 5Y	-50.00%	Gross Margin	29.32%	52W Low	29.05%	ATR (14)	0.03
Dividend Ex-Date	-	Current Ratio	0.28	EPS Y/Y TTM	47.67%	Oper. Margin	-380.19%	RSI (14)	31.32	Volatility	22.73% 15.92%
Employees	4	Debt/Eq	-	Sales Y/Y TTM	-35.10%	Profit Margin	-396.23%	Recom	1.00	Target Price	33.50
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	69.23%	Payout	-	Rel Volume	170.88	Prev Close	0.17
Sales Surprise	-100.00%	EPS Surprise	21.74%	Sales Q/Q	-100.00%	Earnings	-	Avg Volume	162.39K	Price	0.19
SMA20	-24.30%	SMA50	-34.26%	SMA200	-66.91%	Trades		Volume	27,748,214	Change	6.98%

Jun-03-24 10:53AM	QLGN Stock Earnings: Qualigen Therapeutics Beats EPS for Q4 2023 (InvestorPlace)
May-30-24 04:00PM	Qualigen Therapeutics, Inc. Received Nasdaq Notice of a Delisting Determination (GlobeNewswire)
Apr-16-24 07:00AM	Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft (GlobeNewswire) -6.28%
Apr-10-24 08:00AM	Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting (GlobeNewswire)
Apr-09-24 08:00AM	Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting (GlobeNewswire)
Nov-14-23 04:30PM	Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023 (GlobeNewswire)
Nov-07-23 08:30AM	Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors (GlobeNewswire)
Oct-23-23 08:30AM	Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at AACR Special Conference: Advances in Breast Cancer (GlobeNewswire)
Sep-27-23 08:30AM	Qualigen Therapeutics Presents Scientific Data on QN-302 at AACR Special Conference: Pancreatic Cancer 2023 (GlobeNewswire)
Aug-30-23 07:09AM	QLGN: Receives U.S. FDA IND Clearance; Phase 1 Trial to Initiate 2H23 (Zacks)
Aug-17-23 08:30AM	Qualigen Therapeutics Partners with TD2 for Phase 1 Clinical Development of QN-302 for the Treatment of Advanced or Metastatic Solid Tumors (GlobeNewswire)
Aug-15-23 08:30AM	Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending June 30, 2023 (GlobeNewswire)
Aug-01-23 08:30AM	Qualigen Therapeutics Announces US FDA IND Clearance to Initiate Phase 1 Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors (GlobeNewswire)
Jul-24-23 08:15AM	Qualigen Therapeutics Divests FastPack® Diagnostics Business (GlobeNewswire)
Jun-14-23 10:30AM	QLGN: Data for Pan-RAS Platform Presented at ASCO (Zacks Small Cap Research)
Jun-05-23 08:15AM	Poster Highlighting Qualigen Therapeutics Pan-RAS Inhibitor Platform Presented at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting (GlobeNewswire)
May-16-23 08:00AM	Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending March 31, 2023 (GlobeNewswire)
May-12-23 07:20AM	QLGN: IND for QN-302 to be Submitted in Mid-2023 (Zacks Small Cap Research) -5.69%
May-02-23 04:30PM	Qualigen Therapeutics, Inc. Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update (GlobeNewswire) +7.29% -5.98%
08:15AM	Qualigen Therapeutics Pan-RAS Inhibitor Program Highlighted in Two Abstracts at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting (GlobeNewswire)
Apr-21-23 05:46PM	Qualigen Therapeutics, Inc. Receives Nasdaq Notice Regarding Delayed Form 10-K Filing (GlobeNewswire)
Apr-18-23 08:45AM	Qualigen Therapeutics Announces Four Posters on QN-302 Presented at the American Association of Cancer Research (AACR) 2023 Annual Meeting in Orlando, FL (GlobeNewswire) -5.48%
07:30AM	Qualigen Therapeutics Presents Data On QN-247 in Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, FL (GlobeNewswire)
Mar-21-23 08:35AM	Composition of Matter Patent for QN-302 Granted by United States Patent and Trademark Office (GlobeNewswire) +16.33%
Mar-15-23 09:05AM	Qualigen Therapeutics to Present Five Posters at the American Association for Cancer Research Annual Meeting 2023 (GlobeNewswire)
Mar-09-23 08:30AM	Qualigen Therapeutics Presents Data on its RAS Inhibitor Program at the American Association for Cancer Research: Targeting RAS Conference (GlobeNewswire)
Mar-08-23 08:05AM	Data on Potential Biomarker for Qualigen Therapeutics Lead Program QN-302 Published in Peer-Reviewed Journal Molecules (GlobeNewswire) -7.14%
Feb-01-23 09:05AM	Qualigen Therapeutics Chief Executive Officer Michael Poirier Provides Letter to Stockholders (GlobeNewswire) +10.85%
Jan-24-23 09:00AM	Qualigen Therapeutics Initiates Good Laboratory Practice (GLP) Toxicology Studies on QN-302 (GlobeNewswire)
Jan-23-23 09:02AM	Qualigen Therapeutics Promotes Benedict M. Abugan to Vice President, Head of Diagnostics and Corporate Communications (GlobeNewswire)
Jan-10-23 09:00AM	Qualigen Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for QN-302, a G-Quadruplex (G4) Transcription Inhibitor for the Intended Indication of Pancreatic Cancer (GlobeNewswire) +5.51%
Jan-05-23 09:00AM	Qualigen Therapeutics Provides Update on Developments at NanoSynex; Significant Progress Reported on Infectious Disease Diagnostic Platform (GlobeNewswire) +9.73%
Dec-12-22 08:30AM	Qualigen Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule (GlobeNewswire)
Dec-07-22 09:10AM	Qualigen Therapeutics Announces Pre-IND Feedback from U.S. Food and Drug Administration Regarding QN-302 for the Treatment of G4-Targeted Advanced Solid Tumors (GlobeNewswire) -6.21%
Dec-01-22 07:11AM	QLGN: Encouraging Preclinical Data Presented for QN-302 and RAS Inhibitor (Zacks Small Cap Research) +20.20%
Nov-22-22 09:00AM	Qualigen Therapeutics, Inc. Announces 1-for-10 Reverse Stock Split (GlobeNewswire) -14.50%
Nov-17-22 06:12AM	Qualigen Therapeutics Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.)
Nov-15-22 07:30AM	Qualigen Therapeutics, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-19-22 09:00AM	Qualigen Therapeutics Announces Two Posters of Its RAS-Targeted Inhibitor Program at the National Cancer Institute (GlobeNewswire)
Oct-18-22 09:00AM	Qualigen Therapeutics to Present at LD Micro Main Event XV (GlobeNewswire)
Oct-06-22 08:00AM	Qualigen Therapeutics to Present Two Posters at the National Cancer Institute Fourth RAS Initiative Symposium (GlobeNewswire) -10.06%
Sep-14-22 05:02PM	Qualigen Therapeutics Presents Data on QN-302 at AACRs Pancreatic Cancer Meeting (GlobeNewswire) -5.71%
Aug-25-22 06:45AM	QLGN: FastPack Sales Up 28% YoY (Zacks Small Cap Research)
Aug-18-22 09:15AM	Qualigen Therapeutics Announces Formation and First Meeting of QN-302 Scientific Advisory Board (GlobeNewswire)
Aug-16-22 07:30AM	Qualigen Therapeutics, Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-01-22 08:30AM	Qualigen Therapeutics Reports Positive QN-247 Readout in Triple Negative Breast Cancer in Vivo Model (GlobeNewswire)
Jul-06-22 09:00AM	Qualigen Therapeutics Announces Partnership with Hande Sciences To Scale-Up Manufacturing To Support IND-Enabling Studies for QN-302 (GlobeNewswire)
Jun-14-22 09:00AM	Qualigen Therapeutics to Present at BIO International Convention (GlobeNewswire)
Jun-07-22 09:04AM	Qualigen Therapeutics Announces IND-Enabling Studies to Advance Lead Program QN-302 Toward Clinical Trials (GlobeNewswire)
Jun-06-22 06:10AM	QLGN: Acquires Majority Stake in Israeli Diagnostics Technology Company NanoSynex (Zacks Small Cap Research)
Jun-02-22 09:00AM	Qualigen Therapeutics Acquires Majority Stake in Infectious Disease Diagnostics Technology Company NanoSynex (GlobeNewswire) +5.36%
May-26-22 09:15AM	Qualigen Therapeutics Pan-RAS Inhibitor Featured in Two Abstracts at American Society for Clinical Oncology (ASCO) 2022 Annual Meeting (GlobeNewswire)
May-20-22 09:15AM	Qualigen Therapeutics to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire)
May-13-22 06:00AM	Qualigen Therapeutics, Inc. Provides Corporate Update and Reports First Quarter 2022 Financial Results (GlobeNewswire) +7.65%
May-10-22 09:17AM	Qualigen Therapeutics Partner NanoSynex to Present Technology at BioMed Israel (GlobeNewswire)
May-03-22 02:24PM	Qualigen Takes Stake In NanoSynex To Gain Access To Next-Gen Diagnostic Platform (Benzinga)
09:17AM	Qualigen Therapeutics to Acquire Majority Stake in Diagnostics Technology Company NanoSynex (GlobeNewswire)
Apr-29-22 09:15AM	Qualigen Therapeutics Appoints Shishir Sinha to Lead Diagnostics Division Following Promotion to Senior Vice President (GlobeNewswire)
Apr-18-22 06:25AM	QLGN: Secures Worldwide Rights to G4-Selective Cancer Therapeutics (Zacks Small Cap Research) -12.75%
Apr-12-22 10:15AM	Qualigen Therapeutics Presents Three Posters of QN-302 at American Association of Cancer Research Conference (GlobeNewswire) +52.06%
Apr-05-22 09:15AM	Qualigen Therapeutics Resumes Worldwide Distribution and Commercial Control Over FastPack® (GlobeNewswire)
Apr-01-22 08:00AM	Qualigen Therapeutics, Inc. Reports Year-End 2021 Financial Results (GlobeNewswire)
Mar-30-22 09:15AM	Qualigen Therapeutics Engages TD2 as Contract Research Organization for Preclinical Development of QN-302 (GlobeNewswire)
Mar-22-22 09:15AM	Qualigen Therapeutics Announces Three Published Abstracts at American Association of Cancer Research Conference (GlobeNewswire) +8.04%
Mar-15-22 09:15AM	Qualigen Therapeutics Extends Research Agreement with University of Louisville Research Foundation on RAS Program (GlobeNewswire)
Feb-22-22 09:15AM	Qualigen Therapeutics CEO Michael Poirier Provides Letter to Shareholders (GlobeNewswire)
Feb-15-22 09:15AM	Data from Qualigen Therapeutics Lead Program QN-302 Accepted as Three Poster Presentations at AACR 2022 Conference (GlobeNewswire)
Feb-01-22 09:15AM	Qualigen Therapeutics Engages Professor Stephen Neidle as Scientific Advisor in the Development of Lead Program QN-302 (GlobeNewswire)
Jan-18-22 09:15AM	Qualigen Therapeutics Secures Worldwide Rights to G4-Selective Transcription Inhibitors from University College London to Develop as Cancer Therapeutics (GlobeNewswire)
Dec-14-21 09:18AM	Qualigen Therapeutics Promotes Amy Broidrick to President (GlobeNewswire)
Dec-01-21 03:25PM	Qualigen Therapeutics, Inc. Announces Closing of $8.82 Million Registered Direct Offering (GlobeNewswire)
Nov-29-21 03:50PM	QUALIGEN THERAPEUTICS, INC. ANNOUNCES $8.82 MILLION COMMON STOCK REGISTERED DIRECT OFFERING (GlobeNewswire) -7.06%
Nov-22-21 10:23AM	QLGN: Revenues Increase 38% YoY (Zacks Small Cap Research) +25.62%
07:43AM	Here's Why Qualigen Therapeutics (NASDAQ:QLGN) Must Use Its Cash Wisely (Simply Wall St.)
Nov-15-21 09:00AM	Qualigen Therapeutics, Inc. Reports Third Quarter 2021 Financial Results (GlobeNewswire)
Oct-19-21 09:00AM	Peer-Reviewed Article Confirms That Qualigens FastPack® is as Accurate in Thyroid Stimulating Hormone Measurement -- and Much Faster -- Than a Leading Laboratory Method (GlobeNewswire)
Sep-15-21 07:30AM	Qualigen to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (GlobeNewswire) +5.11%
Sep-08-21 07:30AM	Qualigen to Present at the H.C. Wainwright 23rd Annual Global Investment Conference (GlobeNewswire)
Aug-31-21 06:22AM	QLGN: Focusing on Advancement of QN-247 and RAS-F (Zacks Small Cap Research) +22.66%
Aug-23-21 09:58AM	4 Penny Stocks Insiders Are Buying (Benzinga) +7.63%
Aug-17-21 10:01AM	Why Qualigen Therapeutics (QLGN) Stock Plunging After Q2 Update (Benzinga) -22.16%
08:00AM	Qualigen Therapeutics, Inc. Provides Update on Product Development Priorities and Reports Second Quarter and Six Month 2021 Financial Results (GlobeNewswire)
07:02AM	25 Stocks Moving in Tuesday's Pre-Market Session (Benzinga)
Jul-14-21 07:30AM	Qualigen Therapeutics, Inc. Announces Submission of Investigational New Drug (IND) Application for QN-165, for the Treatment of COVID-19 (GlobeNewswire)
Jul-07-21 10:37AM	QLGN: On Track to File IND for QN-165 as COVID-19 Treatment in 2H21 (Zacks Small Cap Research) +7.85%
Jun-08-21 07:30AM	Qualigen Therapeutics Announces Inclusion in Russell Microcap® Index (GlobeNewswire)
Jun-02-21 07:30AM	Qualigen Therapeutics, Inc. to Present at the LD Micro Invitational XI Conference (GlobeNewswire)
May-19-21 07:30AM	Qualigen Therapeutics, Inc. Appoints Tariq Arshad, MD, MBA as Chief Medical Officer (GlobeNewswire)
May-18-21 02:10PM	Qualigen Therapeutics Inc to Host Earnings Call (ACCESSWIRE)
May-14-21 01:35PM	Qualigen Therapeutics, Inc. Reports First Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-26-21 07:00AM	QLGN: IND Filing for QN-165 as COVID-19 Treatment Expected in 2Q21 (Zacks Small Cap Research) +11.44%
07:00AM	QLGN: IND Filing for QN-165 as COVID-19 Treatment Expected in 2H21 (Zacks Small Cap Research)
Apr-19-21 01:16PM	Qualigen Therapeutics Plans to Combat COVID-19 Variants (Benzinga)
Apr-06-21 09:30AM	Is Qualigen Therapeutics (NASDAQ:QLGN) In A Good Position To Invest In Growth? (Simply Wall St.)
Mar-18-21 08:30AM	Qualigen Therapeutics, Inc. to present at the Benzinga Biotech Small Cap Conference (GlobeNewswire)
Mar-09-21 08:30AM	Qualigen Therapeutics, Inc. Promotes Shishir Sinha to Chief Operating Officer Position (GlobeNewswire)
Mar-08-21 08:30AM	Qualigen Therapeutics, Inc. to present at the Oppenheimer 31st Annual Healthcare Conference (GlobeNewswire) +10.07%
Mar-01-21 08:30AM	Qualigen Therapeutics Secures Option to Negotiate License for G-Quadruplex Anti-Cancer Technology from UCL (GlobeNewswire)
Jan-26-21 09:00AM	Qualigen Therapeutics Announces Completion of Milestone Related to the License and Technology Transfer of its FastPack® Diagnostics Products in China (PR Newswire)
Dec-30-20 11:16AM	Insider Buys Qualigen Therapeutics Stock (Benzinga)

Qualigen Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for the treatment of cancer and infectious diseases. The company's cancer therapeutics pipeline includes ALAN (AS1411-GNP), RAS-F3 and STARS. ALAN (AS1411-GNP) is a DNA coated gold nanoparticle cancer drug candidate that has the potential to target various types of cancer with minimal side effects. RAS-F3 is a small molecule RAS oncogene protein-protein inhibitor for blocking RAS mutations that lead to tumor formation, especially in pancreatic, colorectal and lung cancers. STARS is a DNA/RNA-based treatment device for removal from circulating blood of precisely targeted tumor-produced and viral compounds. The company was founded on March 29, 2004 and is headquartered in Carlsbad, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

QLGN

Qualigen Therapeutics Inc

Upgrade your FINVIZ experience